Search results for " Outcome"

showing 10 items of 4574 documents

Unravelling the heterogeneity of soft tissue and bone sarcoma patients’ health-related quality of life: a systematic literature review with focus on …

2020

Contains fulltext : 229532.pdf (Publisher’s version ) (Open Access) Patients with sarcoma experience many physical and psychological symptoms, adversely affecting their health-related quality of life (HRQoL). HRQoL assessment is challenging due to the diversity of the disease. This review aims to unravel the heterogeneity of HRQoL of patients with sarcoma with regard to tumour location and to summarise the used measures in research. English-language literature from four databases published between January 2000 and April 2019 was reviewed. Studies that described adult sarcoma HRQoL outcomes were included and classified according to primary sarcoma location. Eighty-seven articles met the incl…

AdultCancer Researchmedicine.medical_specialtyConstitutional symptomsPopulationbone sarcomaSoft Tissue NeoplasmsReviewBone Sarcomalcsh:RC254-282Quality of lifeInternal medicineSurveys and QuestionnairesMedicineHumans1506educationeducation.field_of_studyOsteosarcomabusiness.industrySoft tissue sarcomaSarcomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanitieshealth-related quality of lifeSystematic reviewOncologypatient-reported outcomessoft tissue sarcomaQuality of LifeSarcomabusinessPsychosocialRare cancers Radboud Institute for Health Sciences [Radboudumc 9]ESMO Open
researchProduct

Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer pr…

2002

The objective of our study was to determine the effect of adding r-metHuSCF to Filgrastim and cyclophosphamide for mobilization of peripheral blood progenitor cells (PBPC), on collection of CD34(+) cells and engraftment after autologous stem cell transplant. Twenty-three patients with previously treated stage II-IV breast cancer received cyclophosphamide (3 g/m(2)), Filgrastim 5 microg/kg daily and r-metHuSCF 20 microg/kg daily. Two PBPC collections were performed on consecutive days starting the day the WBC count was above 7.5 x 10(3)/microl. Collection was performed between days +9 and +12 and the median number of CD34(+) cells collected was 9.9 x 10(6)/kg (1.1-53.1) and 6.6 x 10(6)/kg (1…

AdultCancer Researchmedicine.medical_specialtyFilgrastimPlatelet EngraftmentCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsFilgrastimTransplantation Autologouschemistry.chemical_compoundInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansNeoplasm MetastasisProgenitor cellCyclophosphamideAgedNeoplasm StagingStem Cell FactorChemotherapybusiness.industryHematologyMiddle AgedHematopoietic Stem CellsHematopoietic Stem Cell MobilizationRecombinant ProteinsNitrogen mustardGranulocyte colony-stimulating factorTransplantationTreatment OutcomeEndocrinologyOncologychemistryLymphatic MetastasisFemalebusinessStem Cell Transplantationmedicine.drugLeukemia
researchProduct

Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.

2002

<i>Objective:</i> This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). <i>Methods:</i> Heavily pretreated patients with MBC, aged 18–75 years with World Health Organization performance status of 0–2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m<sup>2</sup>) followed by a weekly fixed dose of gemcitabine, 800 mg/m<sup>2</sup>, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomat…

AdultCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.drug_classmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsDocetaxelWorld Health OrganizationAntimetaboliteGastroenterologyDeoxycytidineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAgedChemotherapyPerformance statusDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyDocetaxelLymphatic MetastasisToxicityFemaleTaxoidsbusinessmedicine.drugOncology
researchProduct

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

2018

Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited.We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions.Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percenta…

AdultCancer Researchmedicine.medical_specialtyTime FactorsReceptor ErbB-2Posterior fossaAge at diagnosisBreast NeoplasmsTriple Negative Breast NeoplasmsYoung Adult03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeRisk FactorsGermanyInternal medicineBiomarkers TumormedicineHumansRegistriesskin and connective tissue diseasesAgedRetrospective StudiesAged 80 and overBrain Neoplasmsbusiness.industryMiddle Agedmedicine.diseaseTreatment OutcomeOncologyHormone receptor030220 oncology & carcinogenesisCohortLife expectancyFemalePrimary breast cancerbusiness030217 neurology & neurosurgeryEuropean Journal of Cancer
researchProduct

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients…

2008

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly highe…

AdultCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentCHOPGastroenterologyDisease-Free SurvivalLymphoplasmacytic LymphomaAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedChemotherapybusiness.industryRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.disease3. Good healthLymphomaSurgeryTreatment OutcomeOncologyDoxorubicinVincristine030220 oncology & carcinogenesisPrednisoneRituximabWaldenstrom MacroglobulinemiaRituximabbusiness030215 immunologymedicine.drugLeukemia
researchProduct

A Case Report of Adult Pineoblastoma Occurring in a Pregnant Woman.

2019

Background/aim Pineoblastoma of the adult age is an uncommon tumor with only 200 cases reported. A standardized approach for an optimal adjuvant strategy is currently lacking. The case presented herein also deals with the issue of central nervous system tumors in pregnancy. Case report A 21-year-old pregnant woman presented with massive hydrocephalus due to a mass in the pineal region detected with MRI. After positioning an urgent ventricular derivation, a cesarean section was performed. During a third ventriculocisternostomy, a biopsy revealed a pineoblastoma. After a maximal safe resection, postoperative craniospinal irradiation for a total dose of 36 Gy plus a sequential boost to the tum…

AdultCancer Researchmedicine.medical_specialtyVincristinePineal GlandCraniospinal IrradiationVentriculostomy03 medical and health sciences0302 clinical medicinePregnancyBiopsyMedicineHumansPineoblastomaPregnancymedicine.diagnostic_testbusiness.industryCesarean SectionGestational ageGeneral MedicineChemoradiotherapy Adjuvantmedicine.diseaseMagnetic Resonance ImagingHydrocephalusAdult PineoblastomaTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologybusinessPinealomaPregnancy Complications Neoplasticmedicine.drugAnticancer research
researchProduct

Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid ar…

2009

The objective of the study is to evaluate the effect of TNF inhibition on carotid thickness over a 2-year period. 144 women with RA diagnosed according to ACR criteria, without clinical evidence of cardiac and/or vascular disease were enrolled and compared with 78 matched controls. All patients received methotrexate (15–20 mg weekly) for 3 months. Responders (n = 79) continued to be treated with methotrexate, non-responders (n = 40) moved to methotrexate plus a TNF alpha antagonist. Echosonographic studies of carotids were obtained before and after 2-year follow-up. A significant decrease of ca-IMT was observed in anti-TNF-treated patients (P < 0.001); on the other hand, no significant vari…

AdultCarotid Artery Diseasesmedicine.medical_specialtyImmunologyTNFGastroenterologyArthritis RheumatoidRheumatologyInternal medicineRheumatoid arthritis TNF DMARDs AtherosclerosisFemale patientmedicineHumansImmunology and AllergyRheumatoid arthritiUltrasonographyTumor Necrosis Factor-alphaVascular diseasebusiness.industryAntagonistMiddle AgedAtherosclerosismedicine.diseaseRheumatologySurgerySettore MED/16 - ReumatologiaDMARDMethotrexateTreatment OutcomeIntima-media thicknessAntirheumatic AgentsRheumatoid arthritiscardiovascular systemDrug Therapy CombinationFemaleMethotrexateTumor necrosis factor alphaTunica IntimaTunica Mediabusinessmedicine.drugRheumatology International
researchProduct

Traumatic damage to the cartilage influences outcome of anatomically reduced acetabular fractures: A medium-term retrospective analysis

2011

We reviewed 77 patients with an acetabular fracture, treated operatively through a non-extensile approach after an average time of 45 months. The ilioinguinal approach was chosen in 41, the Kocher-Langenbeck approach in 36 patients. Following the Letournel classification, the most frequent lesions were posterior wall (26%), two-column (22.1%) and anterior column (14.3%) fractures. Subchondral impaction, intra-articular fracture fragments and fracture comminution, called modifiers, could be identified in the preoperative CT-data of 38 patients (49.4%). Patients were operated after an average of 4 days. Average hospital stay was 19 days. Sciatic nerve and peroneal nerve palsy were registered …

AdultCartilage ArticularMaleReoperationmedicine.medical_specialtyAdolescentArthroplasty Replacement Hipmedicine.medical_treatmentFracture Fixation InternalFractures BoneYoung AdultFracture fixationmedicineHumansFractures ComminutedAgedRetrospective StudiesGeneral Environmental Sciencebusiness.industryImpactionMononeuropathiesAcetabular fractureAcetabulumRetrospective cohort studyMiddle Agedmedicine.diseaseAcetabulumArthroplastySurgeryVenous thrombosisTreatment OutcomeHarris Hip ScoreGeneral Earth and Planetary SciencesFemaleTomography X-Ray ComputedbusinessInjury
researchProduct

The Randomized Shortened Dental Arch Study

2012

The scientific evidence concerning prosthodontic care for the shortened dental arch (SDA) is sparse. This randomized multicenter study aimed to compare two common treatment options: removable partial dental prostheses (RPDPs) for molar replacement vs. no replacement (SDA). One of the hypotheses was that the follow-up treatment differs between patients with RPDPs and patients with SDAs during the 5-year follow-up period. Two hundred and fifteen patients with complete molar loss in one jaw were included in the study. Molars were either replaced by RPDPs or not replaced according to the SDA concept. A mean number of 4.2 (RPDP) and 2.8 (SDA) treatments for biological or technical reasons occur…

AdultChange over timeMolarmedicine.medical_treatmentDentistryDental Abutmentslaw.inventionTooth LossDental ArchRandomized controlled triallawmedicineDenture Precision AttachmentHumansBicuspidProspective StudiesDenture DesignGeneral DentistryObservation timebusiness.industryJaw Edentulous PartiallyTreatment optionsDenture RetentionMolarDental archTreatment Outcomemedicine.anatomical_structureMulticenter studyDenture Partial RemovableProsthodonticsbusinessFollow-Up StudiesJournal of Dental Research
researchProduct

Pregnancy in primary sclerosing cholangitis

2011

Background There is a paucity of data on fertility or pregnancy in patients with primary sclerosing cholangitis (PSC). Objective To assess fertility in PSC by comparing the number of children in a large cohort of PSC patients to healthy controls and to investigate the outcome of pregnancy, as well as the influence of pregnancy on the disease course. Design Case series. Setting Germany. Participants 229 PSC patients and 569 healthy controls were evaluated for the number of children. 17 patients with PSC and at least one pregnancy, or who received a diagnosis of PSC within 6 months after delivery, were included in the more detailed analysis. Main outcome measures Number of children per patien…

AdultCholagogues and Cholereticsmedicine.medical_specialtyTime FactorsAdolescentmedia_common.quotation_subjectCholangitis SclerosingFertilityAutoimmune hepatitisPrimary sclerosing cholangitisYoung AdultPregnancyRisk FactorsGermanyAzathioprinemedicineHumansYoung adultmedia_commonPregnancyFetusObstetricsbusiness.industryIncidenceIncidence (epidemiology)Ursodeoxycholic Aciddigestive oral and skin physiologyInfant NewbornPregnancy OutcomeGastroenterologymedicine.diseasedigestive system diseasesPregnancy ComplicationsImmunologyGestationFemalebusinessImmunosuppressive AgentsFollow-Up StudiesGut
researchProduct